BRPI0407900A - geração de células dendrìticas de células precursoras dentrìticas monocìticas com gm-csf na ausência de citocinas adicionais - Google Patents
geração de células dendrìticas de células precursoras dentrìticas monocìticas com gm-csf na ausência de citocinas adicionaisInfo
- Publication number
- BRPI0407900A BRPI0407900A BRPI0407900-0A BRPI0407900A BRPI0407900A BR PI0407900 A BRPI0407900 A BR PI0407900A BR PI0407900 A BRPI0407900 A BR PI0407900A BR PI0407900 A BRPI0407900 A BR PI0407900A
- Authority
- BR
- Brazil
- Prior art keywords
- csf
- dendritic cells
- monocytes
- cells
- dendritic
- Prior art date
Links
- 210000004443 dendritic cell Anatomy 0.000 title abstract 7
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 title abstract 5
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 title abstract 5
- 210000004027 cell Anatomy 0.000 title abstract 5
- 108090000695 Cytokines Proteins 0.000 title abstract 3
- 102000004127 Cytokines Human genes 0.000 title abstract 3
- 239000002243 precursor Substances 0.000 title 1
- 210000001616 monocyte Anatomy 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 abstract 1
- 108010002350 Interleukin-2 Proteins 0.000 abstract 1
- 108090000978 Interleukin-4 Proteins 0.000 abstract 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 230000035800 maturation Effects 0.000 abstract 1
- 210000005259 peripheral blood Anatomy 0.000 abstract 1
- 239000011886 peripheral blood Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/72—Undefined extracts from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/70—Non-animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/10—Mineral substrates
- C12N2533/12—Glass
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
"GERAçãO DE CéLULAS DENDRìTICAS DE CéLULAS PRECURSORAS DENDRìTICAS MONOCìTICAS COM GM-CSF NA AUSêNCIA DE CITOCINAS ADICIONAIS". A presente invenção refere-se às células dendríticas que podem ser derivadas de várias fontes incluindo monócitos de sangue periférico na presença de apenas GM-CSF sem outras citocinas se os monócitos não foram ativados. Prevenindo-se a ativação, tal como prevenindo-se a ligação das células à superfície do vaso de cultura, os monócitos não requerem a presença de citocinas adicionais, tal como IL-4 ou IL-13, para prevenir a diferenciação em uma linhagem de célula não-dendrítica. As DCs imaturas geradas e mantidas desta maneira foram CD14 e expressaram níveis elevados de CD1a. Na maturação por contato com um agente tal como, por exemplo, BCG e IFN~ <sym>~, as células foram determinadas expressarem moléculas de superfície típicas de células dendríticas maduras purificadas por métodos anteriores e cultivadas na presença de GM-CSF e IL-4. As células dendríticas maduras produzidas de monócitos sem ativação e cultivadas em GM-CSF sozinhas são adequadas para uso em métodos de imunoterapia com base em célula dendrítica, tal como o uso no tratamento de doença, incluindo câncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45101503P | 2003-02-27 | 2003-02-27 | |
| PCT/US2004/006119 WO2004076651A2 (en) | 2003-02-27 | 2004-02-27 | Generation of dendritic cells from monocytic dendritic precursor cells with gm-csf in the absence of additional cytokines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0407900A true BRPI0407900A (pt) | 2006-03-21 |
Family
ID=32927693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0407900-0A BRPI0407900A (pt) | 2003-02-27 | 2004-02-27 | geração de células dendrìticas de células precursoras dentrìticas monocìticas com gm-csf na ausência de citocinas adicionais |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US8389278B2 (pt) |
| EP (1) | EP1604016B1 (pt) |
| JP (1) | JP4762887B2 (pt) |
| KR (2) | KR20110106474A (pt) |
| CN (1) | CN1784488B (pt) |
| AT (1) | ATE420946T1 (pt) |
| AU (2) | AU2004214896A1 (pt) |
| BR (1) | BRPI0407900A (pt) |
| CA (1) | CA2517295C (pt) |
| CY (1) | CY1109099T1 (pt) |
| DE (1) | DE602004019057D1 (pt) |
| DK (1) | DK1604016T3 (pt) |
| ES (1) | ES2321939T3 (pt) |
| HK (1) | HK1086597A1 (pt) |
| IL (1) | IL170512A (pt) |
| MX (1) | MXPA05009178A (pt) |
| NZ (1) | NZ542071A (pt) |
| PL (1) | PL209998B1 (pt) |
| RU (1) | RU2364625C2 (pt) |
| TW (1) | TW200506061A (pt) |
| WO (1) | WO2004076651A2 (pt) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040057935A1 (en) * | 2002-09-20 | 2004-03-25 | Cedars-Sinai Medical Center | Intratumoral delivery of dendritic cells |
| KR101144196B1 (ko) * | 2002-12-06 | 2012-05-21 | 노쓰웨스트 바이오써라퓨틱스, 인크. | 종양 치료를 위한 시험관내 부분 성숙된 수지상 세포를 포함하는 조성물 |
| EP1670513B1 (en) * | 2003-10-06 | 2013-01-23 | Cedars-Sinai Medical Center | Cox-2 inhibitors and dendritic cells for use in the treatment of cancer. |
| WO2005043155A1 (en) * | 2003-10-21 | 2005-05-12 | Cedars-Sinai Medical Center | System and method for the treatment of cancer, including cancers of the central nervous system |
| US7790039B2 (en) * | 2003-11-24 | 2010-09-07 | Northwest Biotherapeutics, Inc. | Tangential flow filtration devices and methods for stem cell enrichment |
| CN101155914B (zh) | 2005-04-08 | 2013-03-06 | 阿戈斯治疗公司 | 树状细胞组合物和方法 |
| US20080254537A1 (en) * | 2005-12-08 | 2008-10-16 | Northwest Biotherapeutics, Inc. | Compositions and Methods for Inducing the Activation of Immature Monocytic Dendritic Cells |
| EP1806395A1 (en) * | 2006-01-06 | 2007-07-11 | Stichting Sanquin Bloedvoorziening | Maturation of dendritic cells |
| WO2008039874A2 (en) | 2006-09-26 | 2008-04-03 | Cedars-Sinai Medical Center | Cancer stem cell antigen vaccines and methods |
| WO2008039969A2 (en) | 2006-09-28 | 2008-04-03 | Cedars-Sinai Medical Center | Cancer vaccines and vaccination methods |
| PL1920781T3 (pl) * | 2006-11-10 | 2015-06-30 | Glycotope Gmbh | Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów |
| KR100896747B1 (ko) | 2007-05-30 | 2009-05-11 | 동아대학교 산학협력단 | 후코이단 또는 그 유사체를 함유하는 수지상 세포의 성숙화유도용 조성물 |
| WO2009155332A1 (en) * | 2008-06-17 | 2009-12-23 | Cedars-Sinai Medical Center | Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors |
| ES2565779T3 (es) | 2008-09-02 | 2016-04-06 | Cedars-Sinai Medical Center | Epítopos CD133 |
| JP2010063404A (ja) * | 2008-09-10 | 2010-03-25 | Olympus Corp | 幹細胞の分離方法 |
| FR2940451B1 (fr) * | 2008-12-18 | 2014-09-12 | Proteus | Procede d'evaluation de l'immunogenicite des proteines |
| EP2427485B1 (en) | 2009-05-07 | 2016-12-07 | ImmunoCellular Therapeutics, Ltd. | Cd133 epitopes |
| US9687537B2 (en) * | 2009-07-24 | 2017-06-27 | Rhode Island Hospital | Dendritic cell vaccines for asparaginyl-β-hydroxylase expressing tumors |
| US8815229B2 (en) | 2009-10-12 | 2014-08-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Granulysin in immunotherapy |
| US20130183343A1 (en) * | 2010-03-15 | 2013-07-18 | The Trustees Of The University Of Pennsylvania | System and Method of Preparing and Storing Activated Mature Dendritic Cells |
| RU2458985C1 (ru) * | 2011-03-18 | 2012-08-20 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт клинической иммунологии" Сибирского отделения Российской академии медицинских наук (ФГБУ "НИИКИ" СО РАМН) | Способ генерации антиген-специфических цитотоксических клеток с противоопухолевой активностью |
| JP5577472B2 (ja) * | 2012-02-10 | 2014-08-20 | 医療法人社団博心厚生会 | 単球増殖剤、単球増殖用培地、単球の製造方法、樹状細胞の製造方法、及び樹状細胞ワクチンの製造方法 |
| EP2956544B1 (en) | 2013-02-14 | 2017-11-01 | Immunocellular Therapeutics Ltd. | Cancer vaccines and vaccination methods |
| CN106029683B (zh) * | 2014-07-23 | 2020-11-10 | 国家纳米科学中心 | 一种抑制肿瘤转移和治疗白血病的多肽和多肽复合物、其制备方法及其应用 |
| CN104098652B (zh) * | 2014-07-23 | 2016-11-09 | 国家纳米科学中心 | 一种抑制肿瘤转移的多肽和多肽复合物、其制备方法及其应用 |
| CA2990640A1 (en) * | 2015-06-30 | 2017-01-05 | Northwest Biotherapeutics, Inc. | Optimally activated dendritic cells that induce an improved or increased anti-tumor immune response |
| RU2749610C2 (ru) | 2015-09-15 | 2021-06-16 | Нортвест Байотерапьютикс, Инк. | Способы, относящиеся к композициям активированных дендритных клеток и к иммунотерапевтическому лечению индивидуумов с прогрессирующим раком |
| CN105483084A (zh) * | 2016-01-04 | 2016-04-13 | 英普乐孚生物技术(上海)有限公司 | 肿瘤抗原靶向性dc细胞的制备方法 |
| KR102159766B1 (ko) * | 2018-11-12 | 2020-09-24 | 조선대학교산학협력단 | 홍조류추출물을 이용한 미성숙수지상세포 분화유도용 배지조성물 및 미성숙수지상세포 분화유도방법 |
| WO2020206267A1 (en) * | 2019-04-03 | 2020-10-08 | Akron Biotechnology, Llc | Cryopreservation and cell culture media |
| EP3984597A4 (en) * | 2019-07-12 | 2023-07-12 | Kyushu University, National University Corporation | DEVELOPMENT OF A THERAPY TO IMPROVE MYOCARDIAL CONTRACTION AND A METHOD OF INHIBITION OF CARDIOMYOCYTE DEATH |
| WO2022235072A1 (ko) * | 2021-05-07 | 2022-11-10 | 아주대학교산학협력단 | 수지상 세포의 배양 방법 |
| CN113881632B (zh) * | 2021-09-29 | 2023-09-29 | 四川省医学科学院·四川省人民医院 | 一种提高dc细胞活性的细胞培养基及培养方法 |
| US20230287080A1 (en) * | 2022-01-20 | 2023-09-14 | 3T Biosciences, Inc. | T cell receptor (tcr) compositions and methods for optimizing antigen reactive t-cells |
| GB2624871A (en) * | 2022-11-29 | 2024-06-05 | Alv B As | Process for preparing a population of dendritic cells and immunotherapy using the same |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE72829T1 (de) * | 1985-06-11 | 1992-03-15 | Us Commerce | In einem serumfreien medium in suspension kultivierte humane monozyten. |
| US5162504A (en) | 1988-06-03 | 1992-11-10 | Cytogen Corporation | Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients |
| ES2215991T3 (es) | 1992-04-01 | 2004-10-16 | The Rockefeller University | Procedimiento para la proliferacion (in vitro) de precursores de celulas dendriticas y su uso para producir inmunogenos. |
| US6010905A (en) * | 1995-01-27 | 2000-01-04 | The United States Of America As Represented By The Department Of Health & Human Services | Method for inducing monocytes to exhibit the phenotype of activated myeloid dendritic cells |
| US5788963A (en) | 1995-07-31 | 1998-08-04 | Pacific Northwest Cancer Foundation | Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy |
| US7659119B2 (en) * | 1996-02-12 | 2010-02-09 | Argos Therapeutics, Inc. | Method and compositions for obtaining mature dendritic cells |
| US20020094545A1 (en) | 2000-11-30 | 2002-07-18 | Harris Paul E. | Growth of human dendritic cells for cancer immunotherapy in closed system using microcarrier beads |
| WO2003010292A2 (en) * | 2001-07-25 | 2003-02-06 | Northwest Biotherapeutics, Inc. | Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors |
| JP2005505270A (ja) * | 2001-09-06 | 2005-02-24 | ノースウエスト バイオセラピューティクス，インコーポレイティド | 単球性樹状細胞およびｔ細胞にｔｈ−１応答をプライミングするための組成物および方法 |
| ES2755552T3 (es) * | 2002-06-19 | 2020-04-22 | Northwest Biotherapeutics Inc | Dispositivos de filtración de flujo tangencial y métodos para el enriquecimiento de leucocitos |
| MXPA05008486A (es) * | 2003-02-10 | 2005-11-17 | Northwest Biotherapeutics Inc | Celulas presentadoras de antigeno cd14+ cultivadas. |
-
2004
- 2004-02-27 DK DK04715780T patent/DK1604016T3/da active
- 2004-02-27 MX MXPA05009178A patent/MXPA05009178A/es active IP Right Grant
- 2004-02-27 RU RU2005129561/13A patent/RU2364625C2/ru active
- 2004-02-27 DE DE602004019057T patent/DE602004019057D1/de not_active Expired - Lifetime
- 2004-02-27 PL PL378291A patent/PL209998B1/pl unknown
- 2004-02-27 WO PCT/US2004/006119 patent/WO2004076651A2/en active Application Filing
- 2004-02-27 AT AT04715780T patent/ATE420946T1/de not_active IP Right Cessation
- 2004-02-27 ES ES04715780T patent/ES2321939T3/es not_active Expired - Lifetime
- 2004-02-27 CA CA2517295A patent/CA2517295C/en not_active Expired - Lifetime
- 2004-02-27 EP EP04715780A patent/EP1604016B1/en not_active Expired - Lifetime
- 2004-02-27 NZ NZ542071A patent/NZ542071A/en not_active IP Right Cessation
- 2004-02-27 CN CN2004800105421A patent/CN1784488B/zh not_active Expired - Fee Related
- 2004-02-27 US US10/789,807 patent/US8389278B2/en not_active Expired - Lifetime
- 2004-02-27 TW TW093105079A patent/TW200506061A/zh unknown
- 2004-02-27 JP JP2006503922A patent/JP4762887B2/ja not_active Expired - Fee Related
- 2004-02-27 AU AU2004214896A patent/AU2004214896A1/en not_active Abandoned
- 2004-02-27 BR BRPI0407900-0A patent/BRPI0407900A/pt not_active Application Discontinuation
- 2004-02-27 KR KR1020117021421A patent/KR20110106474A/ko not_active Application Discontinuation
- 2004-02-27 KR KR1020057016059A patent/KR101201875B1/ko not_active IP Right Cessation
-
2005
- 2005-08-25 IL IL170512A patent/IL170512A/en active IP Right Grant
-
2006
- 2006-06-07 HK HK06106546.0A patent/HK1086597A1/xx not_active IP Right Cessation
-
2009
- 2009-04-14 CY CY20091100437T patent/CY1109099T1/el unknown
-
2010
- 2010-04-01 AU AU2010201319A patent/AU2010201319B2/en not_active Ceased
-
2013
- 2013-03-05 US US13/786,208 patent/US9102917B2/en not_active Expired - Lifetime
-
2015
- 2015-07-30 US US14/814,315 patent/US10731130B2/en not_active Expired - Lifetime
-
2020
- 2020-08-03 US US16/983,300 patent/US11827903B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0407900A (pt) | geração de células dendrìticas de células precursoras dentrìticas monocìticas com gm-csf na ausência de citocinas adicionais | |
| Romani et al. | Proliferating dendritic cell progenitors in human blood. | |
| Lüscher et al. | The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor‐infiltrating lymphocytes | |
| Tibúrcio et al. | Molecular aspects of dendritic cell activation in leishmaniasis: an immunobiological view | |
| BR9815761A (pt) | Processo a vácuo para a fabricação de copolìmeros de siloxano-oxialquileno | |
| BRPI0212545B8 (pt) | método ex vivo ou in vitro para produzir uma população de célula dendrítica madura e método para produzir células t | |
| DE69840739D1 (de) | Methode und Zusammensetzung zur Herstellung von reifen dendritischen Zellen | |
| Clark et al. | Origin and subset distribution of peripheral blood dendritic cells in patients with chronic graft-versus-host disease1 | |
| ECSP066422A (es) | Método para obtener factores citotóxicos provenientes de microorganismos, factores citotóxicos obtenidos y composición farmacéutica y conjunto que los contienen. | |
| HK1142093A1 (en) | Process for the replication of influenza viruses in cell culture, and the influenza viruses obtainable by the process | |
| EP0388201A3 (en) | Curable silicone composition | |
| DE60108661D1 (de) | Herstellung und verwendung von dendritischen zellen | |
| ITVI20050025A1 (it) | Struttura di supporto ergonomica in materiale composito, particolarmente per sostenere parti del corpo umano, nonche' metodo di realizzazione della stessa | |
| Smits et al. | Proinflammatory response of human leukemic cells to dsRNA transfection linked to activation of dendritic cells | |
| GB2440089A (en) | Regeneration system its production and use | |
| AU2001259744A1 (en) | Compositions and methods for producing antigen-presenting cells | |
| BR0203531A (pt) | Método para produzir uma substáncia alvo pelo uso de um microorganismo, e, microorganismo no qual um gene da metanol desidrogenase é introduzido | |
| HUT55787A (en) | Process for producing new thienopirane derivatives | |
| AU2002347030A1 (en) | Cultivation of dispersed mycobacteria | |
| AU4935600A (en) | New vaccine formulations - 2 | |
| EP1927657A3 (en) | Compositions and methods for producing antigen-presenting cells | |
| Sun et al. | Aberrant dendritic cell differentiation initiated by the Mll-Een fusion gene does not require leukemic transformation | |
| KR900018379A (ko) | 암전이 억제인자의 제조방법 | |
| Sakaguchi et al. | Lipid Peroxide Formation and Membrane Damage in Endotoxicosis. | |
| ATE294231T1 (de) | Festes kulturmedium für mikroorganismen und eukaryontische zellen und verfahren zu seiner herstellung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |